{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:30:15Z","timestamp":1768822215779,"version":"3.49.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination for the Improvement of Higher Education Personnel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PADC\u2014Programa de Apoio ao Desenvolvimento Cient\u00edfico da Faculdade de Ci\u00eancias Farmac\u00eauticas"},{"name":"Sao Paulo Research Foundation","award":["13\/25882-6"],"award-info":[{"award-number":["13\/25882-6"]}]},{"name":"Sao Paulo Research Foundation","award":["14\/13192-8"],"award-info":[{"award-number":["14\/13192-8"]}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","award":["130607\/2014-2"],"award-info":[{"award-number":["130607\/2014-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","award":["134389\/2015-8"],"award-info":[{"award-number":["134389\/2015-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Benznidazole (BNZ) is the first-line drug for the treatment of Chagas disease. The drug is available in the form of immediate-release tablets for 100-mg (adult) and 12.5-mg (pediatric) doses. The drug is administered two or three times daily for 60 days. The high frequency of daily administrations and the long period of treatment are factors that significantly contribute to the abandonment of therapy, affecting therapeutic success. Accordingly, this study aimed to evaluate the preclinical pharmacokinetics of BNZ administered as extended-release tablets (200-mg dose) formulated with different types of polymers (hydroxypropyl methylcellulose K4M and K100M), compared to the tablets currently available. The studies were conducted with rabbits, and BNZ quantification was performed in plasma and urine by ultraperformance liquid chromatography methods previously validated. The bioavailability of BNZ was adequate in the administration of extended-release tablets; however, with the administration of the pediatric tablet, the bioavailability was lower than with other tablets, which showed that the clinical use of this formulation should be monitored. The pharmacokinetic parameters demonstrated that the extended-release tablets prolonged drug release from the pharmaceutical matrix and provided an increase in the maintenance of the drug concentration\n            <jats:italic>in vivo<\/jats:italic>\n            , which would allow the frequency of administration to be reduced. Thus, a relative bioavailability study in humans will be planned for implementation of a new product for the treatment of Chagas disease.\n          <\/jats:p>","DOI":"10.1128\/aac.02506-15","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T03:49:32Z","timestamp":1455680972000},"page":"2492-2498","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study"],"prefix":"10.1128","volume":"60","author":[{"given":"Marcelo Gomes","family":"Davan\u00e7o","sequence":"first","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Princ\u00edpios Ativos Naturais e Toxicologia, Araraquara, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Leandro","family":"Campos","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Princ\u00edpios Ativos Naturais e Toxicologia, Araraquara, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talita Atanazio","family":"Rosa","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Tecnologia dos Medicamentos (LTM), Departamento de Ci\u00eancias Farmac\u00eauticas, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias Carvalho","family":"Padilha","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Princ\u00edpios Ativos Naturais e Toxicologia, Araraquara, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro Henao","family":"Alzate","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Princ\u00edpios Ativos Naturais e Toxicologia, Araraquara, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Ara\u00fajo","family":"Rolim","sequence":"additional","affiliation":[{"name":"Colegiado de Ci\u00eancias Farmac\u00eauticas, Universidade Federal do Vale do S\u00e3o Francisco (UNIVASF), Petrolina, Pernambuco, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Jos\u00e9","family":"Rolim-Neto","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Tecnologia dos Medicamentos (LTM), Departamento de Ci\u00eancias Farmac\u00eauticas, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros\u00e2ngela Gon\u00e7alves","family":"Peccinini","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Princ\u00edpios Ativos Naturais e Toxicologia, Araraquara, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02761909000200008"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0074-02762009000900006","article-title":"Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery","volume":"104","author":"Coura JR","year":"2009","unstructured":"Coura JR, Dias JC. 2009. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 104(Suppl 1):31\u201340.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir956"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1504.081450"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.74"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03444.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1155\/2013\/406402","article-title":"A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada","volume":"24","author":"Fearon MA","year":"2013","unstructured":"Fearon MA, Scalia V, Huang M, Dines I, Ndao M, Lagac\u00e9-Wiens P. 2013. A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada. Can J Infect Dis Med Microbiol 24:32\u201334.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.3.659-688.2001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003010"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762011000600001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.04.002"},{"key":"e_1_3_2_13_2","unstructured":"World Health Organization. 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90:33\u201344. http:\/\/www.who.int\/wer\/2015\/wer9006.pdf?ua=1."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002300"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12235"},{"key":"e_1_3_2_16_2","first-page":"347","article-title":"Globalization of Chagas disease (American trypanosomiasis): the situation in Europe and Belgium","volume":"166","author":"Carlier Y","year":"2011","unstructured":"Carlier Y. 2011. Globalization of Chagas disease (American trypanosomiasis): the situation in Europe and Belgium. Bull Mem Acad R Med Belg 166:347\u2013357.","journal-title":"Bull Mem Acad R Med Belg"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01662-13"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00537-10"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1521-1528.2005"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1590\/S0074-02762009000400002","article-title":"Present situation and new strategies for Chagas disease chemotherapy: a proposal","volume":"104","author":"Coura JR","year":"2009","unstructured":"Coura JR. 2009. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104:549\u2013554.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"e_1_3_2_21_2","volume-title":"Proposal for the inclusion of benznidazol pediatric dosage form as treatment for Chagas disease in children younger than 2 years old in the World Health Organization Model List of Essential Medicines for Children","author":"Drugs for Neglected Disease Initiative","year":"2012","unstructured":"Drugs for Neglected Disease Initiative. 2012. Proposal for the inclusion of benznidazol pediatric dosage form as treatment for Chagas disease in children younger than 2 years old in the World Health Organization Model List of Essential Medicines for Children. Drugs for Neglected Disease Initiative (DNDi), Rio de Janeiro, Brazil. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/19\/applications\/Benznidazole_6552_C_NF.pdf. Accessed 10 March 2015."},{"key":"e_1_3_2_22_2","volume-title":"Model list of essential medicines for children","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Model list of essential medicines for children. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/4th_EMLc_FINAL_web_8Jul13.pdf. Accessed 10 July 2015."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.5.715"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3386"},{"key":"e_1_3_2_25_2","volume-title":"Guidance for industry: bioanalytical method validation","author":"Food and Drug Administration","year":"2001","unstructured":"Food and Drug Administration. May 2001. Guidance for industry: bioanalytical method validation. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"e_1_3_2_26_2","volume-title":"Guia para valida\u00e7\u00e3o de m\u00e9todos anal\u00edticos e bioanal\u00edticos","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2003","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. 2003. Resolution no. 899, May 29, 2003. Guia para valida\u00e7\u00e3o de m\u00e9todos anal\u00edticos e bioanal\u00edticos. ANVISA, S\u00e3o Paulo, Brazil. http:\/\/portal.anvisa.gov.br\/wps\/wcm\/connect\/4983b0004745975da005f43fbc4c6735\/RE_899_2003_Determina+a+publica%C3%A7%C3%A3o+do+Guia+para+valida%C3%A7%C3%A3o+de+m%C3%A9todos+anal%C3%ADticos+e+bioanal%C3%ADticos.pdf?MOD=AJPERES. Accessed 10 January 2014."},{"key":"e_1_3_2_27_2","article-title":"Resolution RDC\u2014no. 27, May 17, 2012","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2012","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. 2012. Resolution RDC\u2014no. 27, May 17, 2012. Guia para valida\u00e7\u00e3o de m\u00e9todo bioanal\u00edticos. ANVISA, S\u00e3o Paulo, Brazil. Accessed 10 January 2014.","journal-title":"Guia para valida\u00e7\u00e3o de m\u00e9todo bioanal\u00edticos"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01401-12"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02531-12"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.176"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(84)90541-8"},{"key":"e_1_3_2_32_2","first-page":"2192","article-title":"Multiple-dose kinetics of the trypanosomicide benznidazole in man","volume":"30","author":"Raaflaub J","year":"1980","unstructured":"Raaflaub J. 1980. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 30:2192\u20132194.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_33_2","first-page":"1611","article-title":"Single-dose pharmacokinetics of the trypanosomide benznidazole in man","volume":"29","author":"Raaflaub J","year":"1979","unstructured":"Raaflaub J, Ziegler WH. 1979. Single-dose pharmacokinetics of the trypanosomide benznidazole in man. Arzneimittelforschung 29:1611\u20131614.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_34_2","volume-title":"Food and Drug Administration","author":"Food and Drug Administration","year":"2014","unstructured":"Food and Drug Administration. March 2014. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014General considerations. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510160502"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02506-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02506-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:33:35Z","timestamp":1645475615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02506-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1128\/AAC.02506-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02506-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"2015-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}